Teal is the awareness color of ovarian cancer. Women of Teal is a play on the words "Man of Steel" used to describe Superman. I have found my fellow ovarian cancer survivors to be the strongest, most helpful women in the world. They are truly Women of Teal!
Wednesday, November 30, 2011
Gifts for Survivors
Tuesday, November 29, 2011
Advice from my Christmas Past
Monday, November 28, 2011
Immunization Presentation - Nov 30th
Capital Health presents
IMMUNIZATION UPDATE
Wednesday, November 30, 2011
6:30 – 8:00 p.m.
Capital Health in Hamilton
1445 Whitehorse-Mercerville Rd., Hamilton
Join Doug St. John, Pharm.D. and learn more about current vaccine information. The program will discuss the role vaccines play in healthcare and also explore the controversies surrounding them.
Preregistration Required.
For more information and/or to register for this program, call 609-394-4153. You may also register online at www.events.capitalhealth.org.
Nursing contact hours will be given at this program.
Capital Health is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. PI22-3/10-13.
I thought some of my readers might find this interesting. There are clinical trials for a vaccine for ovarian cancer currently going on at U Penn, The Cancer Treatment Centers of America, NCI and the May Clinic. I hope one day they will be talking about a vaccine every woman can take for Ovarian cancer.
Dee
Every Day is a Blessing!
Wednesday, November 23, 2011
I am thankful for...
Tuesday, November 22, 2011
Doxil Shortage Development
This voluntary decision is a result of an internal BVL review, which indicated that routine preventive maintenance did not happen at a specified time for some manufacturing equipment. This required maintenance included steps to ensure that machinery meet all qualifications before being used again. BVL is halting production to conduct a site-wide assessment to determine the potential impact, if any, and will implement any corrective actions if needed.
This temporary suspension of manufacturing by BVL impacts the production and release of DOXIL®, which is currently in short supply and not available beyond product already allocated to patients in the DOXIL® C.A.R.E.S. Physician Access Program. We are not able to estimate timing when DOXIL® may return to the market as BVL has not provided a commitment on when its manufacturing operations will resume. In light of this situation, patients should speak with their physicians about alternate treatment options.